Genmab and AbbVie announced that the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a bispecific antibody treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival (OS) in the U.S. The trial compared epcoritamab to investigator's choice of chemoimmunotherapy in patients ineligible for stem cell transplant. Despite the setback, epcoritamab remains FDA-approved under accelerated approval and is being further studied in combination therapies and other lymphoma indications. Additional detailed results will be published in a peer-reviewed journal.
AbbVie overcame the loss of exclusivity for its blockbuster drug Humira by successfully growing sales of new drugs Skyrizi and Rinvoq, alongside strategic acquisitions like Allergan. Over the past decade, a $1,000 investment in AbbVie grew to $7,464,...
Four NYSE-listed dividend stocks—UPS, AbbVie, Chevron, and Realty Income—are highlighted for their reliable dividends supported by strong cash flow and long histories of payouts. UPS offers a high yield of about 6.24% with improving dividend coverage...
AbbVie Inc. is trading at all-time highs with a market cap over $500 billion, supported by robust 2026 guidance. The company's Q3 earnings are expected to outperform, mainly due to strong sales from immunology drugs Skyrizi and Rinvoq, projected to g...
AbbVie has submitted a Biologics License Application to the FDA for etentamig, a second-generation bispecific antibody T-cell engager for relapsed or refractory multiple myeloma. In the Phase 3 CERVINO study, etentamig demonstrated significant improv...
AbbVie will report its Q3 2026 earnings before market open on October 30, with shares up 28.55% year to date. Options pricing suggests a roughly 5% price move around the release, indicating high expectations. The company recently trimmed its full-yea...
